^
Association details:
| Biomarker: | VTCN1 underexpression |
|---|---|
| Cancer: | Solid Tumor |
| Drug: | puxitatug samrotecan (AZD8205) (Topoisomerase I inhibitor, B7-H4-targeted antibody-drug conjugate) + saruparib (AZD5305) (PARP1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
2947 / 25 - Preclinical evaluation of a novel B7-H4 targeted antibody-drug conjugate AZD8205 as a single agent and in combination with novel PARP inhibitor and checkpoint blockade
Published date:
03/15/2023
Excerpt:
Combination of AZD8205 and AZD5305 provided higher antitumor activity than monotherapy, even in PARP inhibition-resistant or low B7-H4 expressing PDX tumors….Therapeutic benefit of combining AZD8205 with checkpoint immunotherapies was then evaluated in syngeneic models, demonstrating enhanced antitumor efficacy of AZD8205 when combined with an anti-PD-L1 antibody. These data demonstrate that AZD8205 is a promising therapeutic candidate for the treatment of B7-H4 positive solid tumors.
